


## (S,R,S)-AHPC-Me-C7 ester

|                    |  |
|--------------------|--|
| Cat. No.:          | HY-130640  |
| CAS No.:           | 2639528-48-4   |
| Molecular Formula: | C <sub>32</sub> H <sub>46</sub> N <sub>4</sub> O <sub>6</sub> S  |
| Molecular Weight:  | 614.8  |
| Target:            | E3 Ligase Ligand-Linker Conjugates   |
| Pathway:           | PROTAC   |
| Storage:           | -20°C, sealed storage, away from moisture<br>* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 6.67 mg/mL (10.85 mM); ultrasonic and warming and heat to 60°C

| Solvent                   | Mass  | Concentration |           |            |
|---------------------------|-------|---------------|-----------|------------|
|                           |       | 1 mg          | 5 mg      | 10 mg      |
| Preparing Stock Solutions | 1 mM  | 1.6265 mL     | 8.1327 mL | 16.2655 mL |
|                           | 5 mM  | 0.3253 mL     | 1.6265 mL | 3.2531 mL  |
|                           | 10 mM | 0.1627 mL     | 0.8133 mL | 1.6265 mL  |

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

(S,R,S)-AHPC-Me-C7 ester is a E3 ligase ligand-linker conjugate used to synthesise BCL-X<sub>L</sub> PROTAC degraders<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

Bcl-xL

### REFERENCES

[1]. Khan S, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019 Dec;25(12):1938-1947.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA